Gilead Sciences, Inc. (NASDAQ:GILD) Shareholders to Collect $0.82 Quarterly Dividend

Key Points

• Gilead declared a quarterly dividend of $0.82 per share, or $3.28 annualized, representing a roughly 2.0% yield. Shareholders of record on December 15 will be paid on December 30.
• Gilead’s latest results exceeded expectations, with EPS of $2.55 versus the $2.19 consensus and revenue of $8.30 billion, up 6.8% year over year. Growth was led by its HIV portfolio, particularly Biktarvy.
• The dividend appears well covered, with a 38.5% payout ratio, but future profitability faces risks from a widened loss forecast and an expected 38% Biktarvy price reduction under Medicare changes beginning in 2028.

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) announced a quarterly dividend on Thursday, October 29th. Stockholders of record on Tuesday, December 15th will be paid a dividend of $0.82 per share by the biopharmaceutical company on Wednesday, December 30th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, December 15th.

Gilead Sciences has a dividend payout ratio of 38.5% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Gilead Sciences to earn $9.94 per share next year, which means the company should continue to be able to cover its $3.28 annual dividend with an expected future payout ratio of 33.0%.

Gilead Sciences Trading Up 4.0%

NASDAQ GILD opened at $165.61 on Friday. Gilead Sciences has a twelve month low of $114.02 and a twelve month high of $165.70. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The stock has a market cap of $205.35 billion, a price-to-earnings ratio of -62.03 and a beta of 0.31. The firm's 50 day moving average price is $150.33 and its two-hundred day moving average price is $139.55.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Friday, October 30th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.36. The company had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The business's revenue was up 6.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.47 EPS. Equities analysts anticipate that Gilead Sciences will post -0.48 EPS for the current year.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q3 earnings and revenue exceeded expectations. Gilead reported non-GAAP EPS of $2.55, above the $2.19 consensus estimate, while revenue rose 6.8% year over year to $8.30 billion versus expectations of approximately $7.81 billion. Gilead Sciences third-quarter earnings report
• Positive Sentiment: HIV medicines drove the performance. The company highlighted 16% growth in its base business, led by the Biktarvy HIV franchise, while cancer drug Trodelvy also contributed to sales growth. The results represent Gilead’s strongest sales growth in roughly a decade. Gilead HIV franchise earnings report
• Positive Sentiment: Full-year sales guidance was raised. Gilead now expects 2026 product sales of $31.0 billion to $31.3 billion, up from its previous range of $30.1 billion to $30.4 billion and modestly above Wall Street’s expectations. Gilead raises sales guidance
• Positive Sentiment: The quarterly dividend was maintained. Gilead declared an $0.82-per-share quarterly dividend, or $3.28 annualized, representing an approximately 2% yield based on the provided share price. The dividend is payable December 30 to shareholders of record December 15.
• Neutral Sentiment: Analyst reaction was mixed. Robert W. Baird assigned the shares a Hold rating, suggesting the strong operating results may be balanced by valuation near record levels and uncertainty surrounding the company’s pipeline and future growth.
• Negative Sentiment: Profitability and pricing risks temper the report. Gilead widened its 2026 non-GAAP loss forecast, while Medicare-related changes are expected to reduce Biktarvy’s price by 38% beginning in 2028. These factors could pressure future earnings despite the current sales momentum. Gilead Biktarvy pricing and sales outlook

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.